➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKesson
Boehringer Ingelheim
Express Scripts
AstraZeneca

Last Updated: April 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for SF1126

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug SF1126?

SF1126 is an investigational drug.

There have been 4 clinical trials for SF1126. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2016.

The most common disease conditions in clinical trials are Neoplasms, Unknown Primary, Head and Neck Neoplasms, and Carcinoma, Squamous Cell. The leading clinical trial sponsors are SignalRX Pharmaceuticals, Inc., New Approaches to Neuroblastoma Therapy Consortium, and University of Southern California.

There are twenty-six US patents protecting this investigational drug and two hundred and ten international patents.

Recent Clinical Trials for SF1126
TitleSponsorPhase
A Study of Single Agent SF1126 Inhibitor in Patients With Advanced Hepatocellular CarcinomaUniversity of California, San DiegoPhase 1
A Study of Single Agent SF1126 Inhibitor in Patients With Advanced Hepatocellular CarcinomaSignalRX Pharmaceuticals, Inc.Phase 1
SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway GenesSignalRX Pharmaceuticals, Inc.Phase 2

See all SF1126 clinical trials

Clinical Trial Summary for SF1126

Top disease conditions for SF1126
Top clinical trial sponsors for SF1126

See all SF1126 clinical trials

US Patents for SF1126

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SF1126   Start Trial Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC)   Start Trial
SF1126   Start Trial Antibody drug conjugates Novartis AG (Basel, CH)   Start Trial
SF1126   Start Trial Antibody drug conjugates Novartis AG (Basel, CH)   Start Trial
SF1126   Start Trial Benzothiophene-based selective estrogen receptor downregulators The Board of Trustees of the University of Illinois (Urbana, IL)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for SF1126

Drugname Country Document Number Estimated Expiration Related US Patent
SF1126 Australia AU2015244171 2034-04-11   Start Trial
SF1126 Australia AU2015244179 2034-04-11   Start Trial
SF1126 Canada CA2945128 2034-04-11   Start Trial
SF1126 Canada CA2945129 2034-04-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKesson
Boehringer Ingelheim
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.